BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

920 related articles for article (PubMed ID: 30759826)

  • 1. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
    Xiao X; He Z; Cao W; Cai F; Zhang L; Huang Q; Fan C; Duan C; Wang X; Wang J; Liu Y
    Int J Oncol; 2016 Jun; 48(6):2608-18. PubMed ID: 27082429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
    Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
    Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
    Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
    Yu B; Zheng L; Tang H; Wang W; Lin Y
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
    Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
    Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
    Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
    Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
    Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
    Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.
    Ma W; Xiang Y; Yang R; Zhang T; Xu J; Wu Y; Liu X; Xiang K; Zhao H; Liu Y; Si Y
    J Pharmacol Sci; 2019 Apr; 139(4):304-310. PubMed ID: 30852180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
    Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
    Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells.
    Wang S; Liu C; Lei Q; Wu Z; Miao X; Zhu D; Yang X; Li N; Tang M; Chen Y; Wang W
    Respir Res; 2021 May; 22(1):146. PubMed ID: 33980216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.